The appointment signals readiness to advance EB613 into Phase 3, a key pipeline catalyst. Monitor for trial start timing, enrollment updates, and any future financing needs to fund the Phase 3 program.
Price Chart
Executive Summary
Entera Bio appointed Dr. Riccardo Paolo Camisasca as Chief Medical Officer, effective immediately, to lead late-stage clinical execution ahead of the planned EB613 Phase 3 initiation in osteoporosis. The appointment brings a seasoned global pharmaceutical executive with 30+ years of R&D leadership to the company.
Key Facts
- Dr. Camisasca appointed CMO effective August 18, 2026
- Appointment timed ahead of planned EB613 Phase 3 initiation
- Dr. Camisasca has 30+ years of experience including roles at Sumitomo Pharma, Takeda, and Novartis
- No financial terms of the appointment disclosed in the filing
Financial Impact
No financial terms disclosed; executive hire with no capital allocation or financial impact stated
Risk Factors
- Phase 3 trial execution risk remains the primary binary event
- No financial terms or compensation details provided, making cost assessment impossible
- Clinical-stage company with no approved products or revenue
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001178913-26-004178 |
| Exhibit: exhibit_99-1.htm | 0001178913-26-004178 |
| Document: 0001178913-26-004178-index-headers.html | 0001178913-26-004178 |
| Document: 0001178913-26-004178-index.html | 0001178913-26-004178 |
| Document: 0001178913-26-004178.txt | 0001178913-26-004178 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 12d ago | DEF 14A | $2.77 | awaiting T+60 | — | $2.86 (+3.25%) |
Oct 6, 2026 20d ago | 8-K | $2.53 | awaiting T+60 | — | $2.86 (+13.04%) |
Aug 27, 2026 8w ago | Press Release | $3.08 | awaiting T+60 | — | $2.86 (−7.14%) |
Aug 18, 2026 9w ago | 8-K | $2.89 | awaiting T+60 | — | $2.86 (−1.04%) |
Aug 7, 2026 11w ago | Press Release | $3.04 | awaiting T+60 | — | $2.86 (−5.92%) |
Jul 29, 2026 12w ago | Press Release | $3.00 $3.02 | ▲ +0.67% | ▼ −4.06% | $2.86 (−4.67%) |
Jun 16, 2026 18w ago | Press Release | $1.18 $2.79 | ▲ +136.44% | ▲ +135.44% | $2.86 (+142.37%) |
May 28, 2026 21w ago | Press Release | $1.22 $3.23 | ▲ +164.75% | ▲ +163.02% | $2.86 (+134.43%) |
May 18, 2026 23w ago | EFFECT | $1.23 $2.80 | ▲ +127.64% | ▲ +122.79% | $2.86 (+132.52%) |
May 8, 2026 24w ago | S-3 | $1.17 $2.81 | ▲ +140.17% | ▲ +135.78% | $2.86 (+144.44%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers